Your browser doesn't support javascript.
loading
Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational study.
Hatanaka, Takeshi; Kakizaki, Satoru; Hiraoka, Atsushi; Tada, Toshifumi; Hirooka, Masashi; Kariyama, Kazuya; Tani, Joji; Atsukawa, Masanori; Takaguchi, Koichi; Itobayashi, Ei; Fukunishi, Shinya; Tsuji, Kunihiko; Ishikawa, Toru; Tajiri, Kazuto; Ochi, Hironori; Yasuda, Satoshi; Toyoda, Hidenori; Ogawa, Chikara; Nishimura, Takashi; Shimada, Noritomo; Kawata, Kazuhito; Kosaka, Hisashi; Tanaka, Takaaki; Ohama, Hideko; Nouso, Kazuhiro; Morishita, Asahiro; Tsutsui, Akemi; Nagano, Takuya; Itokawa, Norio; Okubo, Tomomi; Arai, Taeang; Imai, Michitaka; Naganuma, Atsushi; Koizumi, Yohei; Nakamura, Shinichiro; Joko, Kouji; Kaibori, Masaki; Iijima, Hiroko; Hiasa, Yoichi; Kumada, Takashi.
Afiliação
  • Hatanaka T; Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
  • Kakizaki S; Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
  • Hiraoka A; Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
  • Tada T; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Hirooka M; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
  • Kariyama K; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
  • Tani J; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
  • Atsukawa M; Department of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan.
  • Takaguchi K; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Itobayashi E; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
  • Fukunishi S; Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.
  • Tsuji K; Premier Departmental Research of Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Ishikawa T; Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
  • Tajiri K; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
  • Ochi H; Department of Gastroenterology, Toyama University Hospital, Toyama, Japan.
  • Yasuda S; Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Japan.
  • Toyoda H; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
  • Ogawa C; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
  • Nishimura T; Department of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu, Japan.
  • Shimada N; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Hyogo College of Medicine, Nishinomiya, Japan.
  • Kawata K; Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan.
  • Kosaka H; Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Tanaka T; Department of Surgery, Kansai Medical University, Hirakata, Japan.
  • Ohama H; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Nouso K; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Morishita A; Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
  • Tsutsui A; Department of Gastroenterology and Hepatology, Kagawa University, Kagawa, Japan.
  • Nagano T; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
  • Itokawa N; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
  • Okubo T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Arai T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Imai M; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Naganuma A; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
  • Koizumi Y; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
  • Nakamura S; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
  • Joko K; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
  • Kaibori M; Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Japan.
  • Iijima H; Department of Surgery, Kansai Medical University, Hirakata, Japan.
  • Hiasa Y; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Hyogo College of Medicine, Nishinomiya, Japan.
  • Kumada T; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Cancer Med ; 12(5): 5293-5303, 2023 03.
Article em En | MEDLINE | ID: mdl-36226511
ABSTRACT

AIM:

This study compared the efficacy and safety of atezolizumab and bevacizumab (Atez/Bev) in patients with viral and non-viral infection in clinical settings.

METHODS:

We conducted the retrospective cohort study of 323 BCLC stage B or C hepatocellular carcinoma (HCC) patients with Child-Pugh class A, and a performance status of 0 or 1 who started Atez/Bev from September 2020 to December 2021 at 22 institutions in Japan. Patients with viral infection was defined as those who were either serum anti-HCV- Ab or HBs-Ag-positive, while patients with non-viral infection was defined as those who were both serum anti-HCV Ab- and HBs-Ag-negative. We constructed a propensity-score-matched cohort to minimize the risk of observable potential confounders.

RESULTS:

Propensity score matching produced 126 matched pairs for patients with viral versus non-viral infection. After matching, the significant differences in baseline demographic features did not exist between the two groups. The objective response rate was 20.6% and 24.6% in viral- and non-viral-related HCC patients, respectively, without a significant difference (p = 0.55). The disease control rate was not also significantly different (68.3% vs 69.0%, p = 1.00). The median progression-free survival was 7.0 months (95% confidence interval [CI] 6.0-9.6) and 6.2 months (95% CI 5.1-7.8) in patients with viral and non-viral infection, and the 12-month survival rates were 65.5% (95% CI 50.8-76.8) and 71.7% (95% CI 57.3-81.9) in those with viral and non-viral infection, respectively, which were not significantly different (p = 0.33, p = 0.38). No significant difference in treatment-related adverse events was found between the two groups.

CONCLUSIONS:

Our etiology-based study demonstrated that Atez/Bev showed good efficacy and safety for HCC patient with non-viral infection as well as those with viral infection.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Cancer Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Cancer Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão